10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
With Sanofi and Regeneron’s Dupixent (dupilumab) dominating the current standard of care in atopic dermatitis, new monoclonal antibody (MAb) treatments such as Novartis’ MOR106 are unlikely to overthrow it, says analyst. 10 August 2018
For the second time in four months, Japanese drugmaker Kyowa Hakko Kirin is celebrating receiving US Food and Drug Administration (FDA) approval for a rare disease drug. 9 August 2018
Shares in Sarepta Therapeutics were up 12% at lunchtime on Thursday, after the RNA therapy specialist announced a $30 million deal with Lacerta Therapeutics which added three CNS gene therapies to its pipeline. 9 August 2018
A Chinese oncology company that is developing biosimilars and innovative drugs, has announced the completion of a Series B financing round, raising $102 million in capital. 9 August 2018
Digital medicine company Akili Interactive Labs, an independent affiliate of the biotech company PureTech Health, has announced an additional $13 million worth of investment in its ongoing Series C funding campaign, which now totals $68 million. 9 August 2018
Danish biotech firm Genmab has released its financial results for the first half of 2018, showing that revenues for the period were up 16% at 1.19 billion Danish kroner ($184.9 million). 9 August 2018
Industry analyst GlobalData has drawn attention to a pioneering stem cell trial for Parkinson’s disease underway at Kyoto University Hospital in Japan. 8 August 2018
The US Food and Drug Administration as approved Orkambi (lumacaftor/ivacaftor) to include use in children ages two through five years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation. 8 August 2018
Spark Therapeutics was down 28% on Tuesday lunchtime following a serious adverse event during Phase II trials of their experimental hemophilia A genetic therapy. 7 August 2018
The industry-funded ARM Foundation for Cell and Gene Medicine has launched a new health economic analysis of regenerative medicine therapies, which includes a review of academic literature, health technology assessments, and value frameworks. 7 August 2018
The US Food and Drug Administration has granted Breakthrough Therapy designation for Braftovi (encorafenib), in combination with Mektovi (binimetinib) and cetuximab, intended to expedite development and review of drugs for serious conditions, where preliminary clinical evidence indicates that they may demonstrate substantial improvement over existing therapies. 7 August 2018
Shares in Ironwood Pharmaceuticals closed 4% down on Monday after the US biotech announced that it was ending its agreement with AstraZenecaover lesinurad, a gout drug marketed under the name Zurampic. 7 August 2018
USA-based Acadia Pharmaceuticals has entered into an exclusive North American License Agreement for the development and commercialization of the Australian biotech firm Neuren Pharmaceutical’s trofinetide for Rett syndrome and other indications. 7 August 2018
Samumed, a US biopharmaceutical startup, has concluded its Series A fundraising campaign having raised $438 million based on a valuation of $12 billion. 6 August 2018
Alzheon, a privately-held biopharmaceutical company with a focus on Alzheimer's, announced on Monday that researchers had discovered a naturally-occurring substance in the human brain that suppresses the production of a protein linked to the disease. 6 August 2018
The China National Drug Administration (CNDA) has approved Genvoya (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg or E/C/F/TAF) for the treatment of HIV-1 infection. 6 August 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024